Harvard Management Co. Inc. Purchases Shares of 637,528 Maze Therapeutics, Inc. (NASDAQ:MAZE)

Key Points

• Harvard Management Co. Inc. has acquired a new position in Maze Therapeutics, Inc., purchasing 637,528 shares valued at approximately $7 million, making it the 12th largest holding in their portfolio.
• Maze Therapeutics stock is currently rated as a "Buy" by analysts, with a consensus price target of $25.60 following positive coverage from firms like Wedbush and HC Wainwright.
• Despite the recent investment and favorable analyst ratings, Maze Therapeutics has faced a decline in stock price, currently trading at $14.51, down 4.9%.

Harvard Management Co. Inc. acquired a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 637,528 shares of the company's stock, valued at approximately $7,019,000. Maze Therapeutics accounts for approximately 0.6% of Harvard Management Co. Inc.'s investment portfolio, making the stock its 12th largest position. Harvard Management Co. Inc. owned approximately 1.46% of Maze Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in MAZE. Alphabet Inc. purchased a new stake in Maze Therapeutics during the first quarter worth about $26,561,000. New York State Common Retirement Fund acquired a new position in shares of Maze Therapeutics in the first quarter valued at approximately $25,000. Bank of New York Mellon Corp purchased a new stake in Maze Therapeutics during the 1st quarter worth approximately $190,000. Bessemer Group Inc. acquired a new stake in Maze Therapeutics during the 1st quarter worth approximately $5,305,000. Finally, General Catalyst Group Management LLC purchased a new position in Maze Therapeutics in the 1st quarter valued at approximately $11,405,000.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MAZE. Wedbush assumed coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective on the stock. HC Wainwright started coverage on Maze Therapeutics in a research note on Wednesday, July 23rd. They set a "buy" rating and a $34.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $25.60.

Maze Therapeutics Stock Down 6.5%

NASDAQ MAZE traded down $0.93 on Thursday, hitting $13.32. 156,197 shares of the stock were exchanged, compared to its average volume of 151,889. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $19.19. The firm has a 50-day simple moving average of $13.84.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.